A pretreatment PSA level of 7 to 10 Ng/mL is an independent predictor of adverse biochemical disease free survival among low risk prostate cancer patients treated with I-125 brachytherapy

被引：0
|
作者：
Cesaretti, J. A. [1 ]
Stone, N. N. [1 ]
Kao, J. [1 ]
Stock, R. G. [1 ]
机构：
[1] Mt Sinai Sch Med, New York, NY USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2008年 / 72卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2008.06.1066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S304 / S305
页数：2
相关论文
共 22 条
  • [21] Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effects
    Moll, Matthias
    Paschen, Christopher
    Zaharie, Alexandru
    Berndl, Florian
    Goldner, Gregor
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (02) : 118 - 123
  • [22] The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b
    Porcaro, Antonio Benito
    Panunzio, Andrea
    Orlando, Rossella
    Montanaro, Francesca
    Baielli, Alberto
    Artoni, Francesco
    Gallina, Sebastian
    Bianchi, Alberto
    Mazzucato, Giovanni
    Serafin, Emanuele
    Patuzzo, Giulia Marafioti
    Veccia, Alessandro
    Rizzetto, Riccardo
    Brunelli, Matteo
    Migliorini, Filippo
    Bertolo, Riccardo
    Tafuri, Alessandro
    Cerruto, Maria Angela
    Antonelli, Alessandro
    INTERNATIONAL BRAZ J UROL, 2024, 50 (04): : 450 - 458
123